Nicardipine Hydrochloride
Product Images NDC 51662-1428

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Nicardipine Hydrochloride (NDC 51662-1428). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Labeling (51662 1428 1 Bag Labeling)

NICARDIPINE HYDROCHLORIDE injection in a 200 mL clear plastic IV bag labeled as CARDENE I.V. The concentration is 20 mg per 200 mL (0.1 mg/mL) with 4.8% dextrose. The label shows instructions, warnings, and manufacturer information from HF Acquisition Co LLC, DBA HealthFirst.*

FDA Label Image

Carton Labeling (51662 1428 1 Box Labeling)

Packaging label for Cardene I.V. (nicardipine hydrochloride) premixed injection in 4.8% dextrose. The label shows the concentration as 20 mg in 200 mL (0.1 mg/mL) and indicates it is Rx only. The label states the product contains 10 Galaxy single-dose containers and is marketed by HF Acquisition Co LLC, DBA HealthFirst. Additional details on dosage, storage, and manufacturing information are also included on the label.*

FDA Label Image

Serialized Labeling (51662 1428 1 Serialized Box Labeling)

Cardene I.V. (nicardipine hydrochloride) premixed injection in 4.8% dextrose, 20 mg in 200 mL (0.1 mg/mL) solution. The label shows sterile, nonpyrogenic formulation with detailed composition including dextrose, citric acid, sorbitol, and pH adjusters. Marketed by Chiesi USA, Inc. and manufactured by Baxter Healthcare Corporation. Contains lot number and expiration date AUG 21. Additional dosage and storage instructions are also presented.*

FDA Label Image

Adverse (Adverse)

A data table comparing the incidence of selected adverse events between Cardene I.V. and placebo groups. Categories include Body as a Whole (headache), Cardiovascular (hypotension, tachycardia), and Digestive (nausea/vomiting) with respective counts and percentages for each group.*

FDA Label Image

Dosage (Dosage)

A table showing oral Cardene doses with equivalent IV infusion rates for two concentrations: 20 mg in 200 mL (0.1 mg/mL) and 40 mg in 200 mL (0.2 mg/mL). It lists doses of 20 mg, 30 mg, and 40 mg every 8 hours (q8h), with corresponding infusion rates in mg/hr and mL/hr for each concentration.*

FDA Label Image

How Supplied 1 (How Supplied 1)

Table listing pack sizes, diluents, and corresponding NDC numbers for NICARDIPINE HYDROCHLORIDE bags. It shows 10 bags per pack with 20 mg in 200 mL (0.1 mg/mL) using either 4.8% Dextrose or 0.86% Sodium Chloride as diluent, and 10 bags with 40 mg in 200 mL (0.2 mg/mL) with 0.83% Sodium Chloride. Each entry includes a specific NDC number.*

FDA Label Image

How Supplied 2 (How Supplied 2)

Text panel showing manufacturing and marketing information for NICARDIPINE HYDROCHLORIDE. It states the product is manufactured by Baxter Healthcare Corporation in Deerfield, IL, USA, and marketed by Chiesi USA, Inc. in Cary, NC, USA.*

FDA Label Image

Highlights 1 (Highlights 1)

Table presenting the equivalent intravenous (I.V.) infusion rates for different Oral Cardene doses. It compares infusion rates for two concentrations (0.1 mg/mL and 0.2 mg/mL), showing I.V. rate in mg/hr and corresponding volume in mL/hr for 20 mg, 30 mg, and 40 mg doses given every 8 hours.*

FDA Label Image

Highlights 2 (Highlights 2)

A conversion table showing dosage rates in mg/hr and their equivalent intravenous infusion rates at concentrations of 0.1 mg/mL and 0.2 mg/mL. The table provides three mg/hr values (5, 2.5, and 15) with corresponding infusion rates in mL/hr for each concentration.*

FDA Label Image

Structure (Structure)

Chemical structure of Nicardipine Hydrochloride showing its molecular formula C26H29N3O6·HCl with detailed atomic bonds and functional groups including a nitro-substituted aromatic ring and dihydropyridine core.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.